expert video report on amivantamab in combination therapy for 1l treatment in egfrm, advanced nsclc
Published 9 months ago • 1.6K plays • Length 5:18Download video MP4
Download video MP3
Similar videos
-
4:17
highlights on amivantamab after progression on osimertinib in egfr-mutated nsclc: mariposa-2
-
4:31
expert video report on combination treatments in first-line oncogene addicted advanced nsclc
-
6:20
asco 2023 highlights on adjuvant osimertinib in resected egfr mutated nsclc: the adaura trial
-
4:47
asco 2023 expert report on novelties in oncogene driven nsclc by a. curioni-fontecedro
-
2:28
amivantamab in patients with egfr ex20ins-mutated nsclc
-
6:09
expert video report on therapeutic advances in nsclc from 2021 asco annual meeting
-
10:09
esmo 2020 expert video report on long term ici outcomes in lung cancer
-
1:02
dr reckamp on amivantamab in egfr exon 20–mutated nsclc
-
16:45
amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve egfrm nsclc
-
5:50
#esmo21 expert video report on novelties in metastatic nsclc
-
7:00
expert report on neoadjuvant immune checkpoint inhibitors for nsclc
-
2:12
esmo 2020 highlights on adjuvant osimertinib for egfr mutated nsclc: the adaura study
-
1:26
the challenge of treatment resistance in patients with advanced egfr-mutated nsclc
-
1:34
pros in papillon trial: amivantamab chemo for egfr exon 20 nsclc
-
3:17
phase iii mariposa: amivantamab lazertinib vs osimertinib in egfr-mutated nsclc
-
58:24
time for even more precision in testing and treatment of egfr-mutated nsclc
-
2:03
amivantamab and lazertinib in treatment-naïve egfr-mutant nsclc
-
3:16
#esmo22 highlights on tils versus ipilimumab in patients with advanced melanoma: the phase 3 study
-
3:44
aacr 2023 highlights on advances in the neoadjuvant treatment of resectable nsclc with john heymach